duoset enzyme linked immunosorbent assay kits Search Results


97
R&D Systems tnf⍺ duoset elisa
High concentration of CFTR modulators (Elexacaftor [VX445], Tezacaftor [VX661], and Ivacaftor [VX770]) impairs macrophage control of A. fumigatus growth. ( A ) Measurement of A. fumigatus fungal length (Strain: DAL-DSred) infecting bone marrow-derived macrophages (BMDM) at a multiplicity of infection (MOI) of 5, using the IncuCyte live-cell analysis system in the presence of 3VX (VX445/VX661/VX770) treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. * P < 0.05, ** P < 0.01 (two-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3. ( B ) Release of <t>TNF⍺</t> in BMDMs was assessed after 20 h with A. fumigatus (MOI of 15). ** P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 4. ( C ) Normalized phagocytosis to vehicle control ([Veh]) at 20 h time point. **P < 0.01 , ****P < 0.005 (one sample t test, theoretical mean of 1); data are presented as mean ± SEM, n = 4. ( D ) Representative measurement of zymosan phagocytosis by primed BMDMs in the presence of 3VX treatment at concentrations [3VX] S , [3VX] E or [3VX] 10μM , as well as in the presence of cytochalasine D or [Veh]. ( E ) Quantification of viable conidia following 4 h of BMDM infection in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. ( F ) Immunoblot analysis of pro-caspase-1 ( P45 ), the caspase-1 subunit p20 ( P20 ), and β-actin of primed BMDMs left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh] during 20 h after infection with A. fumigatus (MOI of 15). ( G ) Release of IL-1β in BMDMs assessed after 20 h infection with A. fumigatus (MOI of 15) left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. *P < 0.05 , **P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3.
Tnf⍺ Duoset Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/duoset+enzyme+linked+immunosorbent+assay+kits/Mouse+TNF-alpha+DuoSet+ELISA/pmc12403852-97-13-17
Average 97 stars, based on 1 article reviews
tnf⍺ duoset elisa - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier

96
R&D Systems protein based elisa like assay
High concentration of CFTR modulators (Elexacaftor [VX445], Tezacaftor [VX661], and Ivacaftor [VX770]) impairs macrophage control of A. fumigatus growth. ( A ) Measurement of A. fumigatus fungal length (Strain: DAL-DSred) infecting bone marrow-derived macrophages (BMDM) at a multiplicity of infection (MOI) of 5, using the IncuCyte live-cell analysis system in the presence of 3VX (VX445/VX661/VX770) treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. * P < 0.05, ** P < 0.01 (two-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3. ( B ) Release of <t>TNF⍺</t> in BMDMs was assessed after 20 h with A. fumigatus (MOI of 15). ** P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 4. ( C ) Normalized phagocytosis to vehicle control ([Veh]) at 20 h time point. **P < 0.01 , ****P < 0.005 (one sample t test, theoretical mean of 1); data are presented as mean ± SEM, n = 4. ( D ) Representative measurement of zymosan phagocytosis by primed BMDMs in the presence of 3VX treatment at concentrations [3VX] S , [3VX] E or [3VX] 10μM , as well as in the presence of cytochalasine D or [Veh]. ( E ) Quantification of viable conidia following 4 h of BMDM infection in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. ( F ) Immunoblot analysis of pro-caspase-1 ( P45 ), the caspase-1 subunit p20 ( P20 ), and β-actin of primed BMDMs left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh] during 20 h after infection with A. fumigatus (MOI of 15). ( G ) Release of IL-1β in BMDMs assessed after 20 h infection with A. fumigatus (MOI of 15) left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. *P < 0.05 , **P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3.
Protein Based Elisa Like Assay, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/duoset+enzyme+linked+immunosorbent+assay+kits/Hyaluronan+DuoSet+ELISA/med_rxiv__64898__2026__03__10__26348053-114-14-18
Average 96 stars, based on 1 article reviews
protein based elisa like assay - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

94
R&D Systems human haptoglobin duoset elisa
High concentration of CFTR modulators (Elexacaftor [VX445], Tezacaftor [VX661], and Ivacaftor [VX770]) impairs macrophage control of A. fumigatus growth. ( A ) Measurement of A. fumigatus fungal length (Strain: DAL-DSred) infecting bone marrow-derived macrophages (BMDM) at a multiplicity of infection (MOI) of 5, using the IncuCyte live-cell analysis system in the presence of 3VX (VX445/VX661/VX770) treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. * P < 0.05, ** P < 0.01 (two-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3. ( B ) Release of <t>TNF⍺</t> in BMDMs was assessed after 20 h with A. fumigatus (MOI of 15). ** P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 4. ( C ) Normalized phagocytosis to vehicle control ([Veh]) at 20 h time point. **P < 0.01 , ****P < 0.005 (one sample t test, theoretical mean of 1); data are presented as mean ± SEM, n = 4. ( D ) Representative measurement of zymosan phagocytosis by primed BMDMs in the presence of 3VX treatment at concentrations [3VX] S , [3VX] E or [3VX] 10μM , as well as in the presence of cytochalasine D or [Veh]. ( E ) Quantification of viable conidia following 4 h of BMDM infection in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. ( F ) Immunoblot analysis of pro-caspase-1 ( P45 ), the caspase-1 subunit p20 ( P20 ), and β-actin of primed BMDMs left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh] during 20 h after infection with A. fumigatus (MOI of 15). ( G ) Release of IL-1β in BMDMs assessed after 20 h infection with A. fumigatus (MOI of 15) left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. *P < 0.05 , **P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3.
Human Haptoglobin Duoset Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/duoset+enzyme+linked+immunosorbent+assay+kits/Human+Haptoglobin+DuoSet+ELISA/10__1186_slash_s41231___021___00088___z-68-7-11
Average 94 stars, based on 1 article reviews
human haptoglobin duoset elisa - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

94
R&D Systems duoset elisa
High concentration of CFTR modulators (Elexacaftor [VX445], Tezacaftor [VX661], and Ivacaftor [VX770]) impairs macrophage control of A. fumigatus growth. ( A ) Measurement of A. fumigatus fungal length (Strain: DAL-DSred) infecting bone marrow-derived macrophages (BMDM) at a multiplicity of infection (MOI) of 5, using the IncuCyte live-cell analysis system in the presence of 3VX (VX445/VX661/VX770) treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. * P < 0.05, ** P < 0.01 (two-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3. ( B ) Release of <t>TNF⍺</t> in BMDMs was assessed after 20 h with A. fumigatus (MOI of 15). ** P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 4. ( C ) Normalized phagocytosis to vehicle control ([Veh]) at 20 h time point. **P < 0.01 , ****P < 0.005 (one sample t test, theoretical mean of 1); data are presented as mean ± SEM, n = 4. ( D ) Representative measurement of zymosan phagocytosis by primed BMDMs in the presence of 3VX treatment at concentrations [3VX] S , [3VX] E or [3VX] 10μM , as well as in the presence of cytochalasine D or [Veh]. ( E ) Quantification of viable conidia following 4 h of BMDM infection in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. ( F ) Immunoblot analysis of pro-caspase-1 ( P45 ), the caspase-1 subunit p20 ( P20 ), and β-actin of primed BMDMs left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh] during 20 h after infection with A. fumigatus (MOI of 15). ( G ) Release of IL-1β in BMDMs assessed after 20 h infection with A. fumigatus (MOI of 15) left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. *P < 0.05 , **P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3.
Duoset Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/duoset+enzyme+linked+immunosorbent+assay+kits/Human+Total+MMP-8+DuoSet+ELISA/pmc08164446-108-19-21
Average 94 stars, based on 1 article reviews
duoset elisa - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

95
R&D Systems mouse mip 2 elisa kit
High concentration of CFTR modulators (Elexacaftor [VX445], Tezacaftor [VX661], and Ivacaftor [VX770]) impairs macrophage control of A. fumigatus growth. ( A ) Measurement of A. fumigatus fungal length (Strain: DAL-DSred) infecting bone marrow-derived macrophages (BMDM) at a multiplicity of infection (MOI) of 5, using the IncuCyte live-cell analysis system in the presence of 3VX (VX445/VX661/VX770) treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. * P < 0.05, ** P < 0.01 (two-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3. ( B ) Release of <t>TNF⍺</t> in BMDMs was assessed after 20 h with A. fumigatus (MOI of 15). ** P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 4. ( C ) Normalized phagocytosis to vehicle control ([Veh]) at 20 h time point. **P < 0.01 , ****P < 0.005 (one sample t test, theoretical mean of 1); data are presented as mean ± SEM, n = 4. ( D ) Representative measurement of zymosan phagocytosis by primed BMDMs in the presence of 3VX treatment at concentrations [3VX] S , [3VX] E or [3VX] 10μM , as well as in the presence of cytochalasine D or [Veh]. ( E ) Quantification of viable conidia following 4 h of BMDM infection in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. ( F ) Immunoblot analysis of pro-caspase-1 ( P45 ), the caspase-1 subunit p20 ( P20 ), and β-actin of primed BMDMs left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh] during 20 h after infection with A. fumigatus (MOI of 15). ( G ) Release of IL-1β in BMDMs assessed after 20 h infection with A. fumigatus (MOI of 15) left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. *P < 0.05 , **P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3.
Mouse Mip 2 Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/duoset+enzyme+linked+immunosorbent+assay+kits/Mouse+CXCL2%2FMIP-2+DuoSet+ELISA/10__1164_slash_rccm__200302___303oc-64-12-21
Average 95 stars, based on 1 article reviews
mouse mip 2 elisa kit - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

91
R&D Systems mouse akt 1
High concentration of CFTR modulators (Elexacaftor [VX445], Tezacaftor [VX661], and Ivacaftor [VX770]) impairs macrophage control of A. fumigatus growth. ( A ) Measurement of A. fumigatus fungal length (Strain: DAL-DSred) infecting bone marrow-derived macrophages (BMDM) at a multiplicity of infection (MOI) of 5, using the IncuCyte live-cell analysis system in the presence of 3VX (VX445/VX661/VX770) treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. * P < 0.05, ** P < 0.01 (two-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3. ( B ) Release of <t>TNF⍺</t> in BMDMs was assessed after 20 h with A. fumigatus (MOI of 15). ** P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 4. ( C ) Normalized phagocytosis to vehicle control ([Veh]) at 20 h time point. **P < 0.01 , ****P < 0.005 (one sample t test, theoretical mean of 1); data are presented as mean ± SEM, n = 4. ( D ) Representative measurement of zymosan phagocytosis by primed BMDMs in the presence of 3VX treatment at concentrations [3VX] S , [3VX] E or [3VX] 10μM , as well as in the presence of cytochalasine D or [Veh]. ( E ) Quantification of viable conidia following 4 h of BMDM infection in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. ( F ) Immunoblot analysis of pro-caspase-1 ( P45 ), the caspase-1 subunit p20 ( P20 ), and β-actin of primed BMDMs left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh] during 20 h after infection with A. fumigatus (MOI of 15). ( G ) Release of IL-1β in BMDMs assessed after 20 h infection with A. fumigatus (MOI of 15) left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. *P < 0.05 , **P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3.
Mouse Akt 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/duoset+enzyme+linked+immunosorbent+assay+kits/Human%2FMouse%2FRat+Total+Akt1+DuoSet+IC+ELISA/pm32246616-131-68-71
Average 91 stars, based on 1 article reviews
mouse akt 1 - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier

95
R&D Systems mmp
High concentration of CFTR modulators (Elexacaftor [VX445], Tezacaftor [VX661], and Ivacaftor [VX770]) impairs macrophage control of A. fumigatus growth. ( A ) Measurement of A. fumigatus fungal length (Strain: DAL-DSred) infecting bone marrow-derived macrophages (BMDM) at a multiplicity of infection (MOI) of 5, using the IncuCyte live-cell analysis system in the presence of 3VX (VX445/VX661/VX770) treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. * P < 0.05, ** P < 0.01 (two-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3. ( B ) Release of <t>TNF⍺</t> in BMDMs was assessed after 20 h with A. fumigatus (MOI of 15). ** P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 4. ( C ) Normalized phagocytosis to vehicle control ([Veh]) at 20 h time point. **P < 0.01 , ****P < 0.005 (one sample t test, theoretical mean of 1); data are presented as mean ± SEM, n = 4. ( D ) Representative measurement of zymosan phagocytosis by primed BMDMs in the presence of 3VX treatment at concentrations [3VX] S , [3VX] E or [3VX] 10μM , as well as in the presence of cytochalasine D or [Veh]. ( E ) Quantification of viable conidia following 4 h of BMDM infection in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. ( F ) Immunoblot analysis of pro-caspase-1 ( P45 ), the caspase-1 subunit p20 ( P20 ), and β-actin of primed BMDMs left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh] during 20 h after infection with A. fumigatus (MOI of 15). ( G ) Release of IL-1β in BMDMs assessed after 20 h infection with A. fumigatus (MOI of 15) left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. *P < 0.05 , **P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3.
Mmp, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/duoset+enzyme+linked+immunosorbent+assay+kits/Human+Total+MMP-1+DuoSet+ELISA/pmc04152784-146-3-7
Average 95 stars, based on 1 article reviews
mmp - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

96
R&D Systems hyaluronan duoset elisa development kit
Figure 1. Characterization of the proteoglycan 4 (PRG4) enzyme- linked immunosorbent assay control by protein staining (A) and characterization of high molecular weight PRG4 immunoreactivity in PRG4 control, normal (NL) human synovial fluid (hSF), and osteo- arthritic (OA) SF samples by Western blotting using antipeptide antibody LPN (capture) (B) and horseradish peroxidase (HRP)– conjugated peanut agglutinin (PNA) (detection) (C). Samples were subjected to 3–8% sodium dodecyl sulfate–polyacrylamide gel electro- phoresis, followed by protein staining or Western blotting as described in Materials and Methods. PRG4 controls treated with neuraminidase and SF treated with hyaluronidase and neuraminidase were probed with LPN and with HRP–conjugated PNA.
Hyaluronan Duoset Elisa Development Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/duoset+enzyme+linked+immunosorbent+assay+kits/Hyaluronan+DuoSet+ELISA/pm22933061-75-1-9
Average 96 stars, based on 1 article reviews
hyaluronan duoset elisa development kit - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

94
R&D Systems human s100a9 duoset elisa
Figure 1. Characterization of the proteoglycan 4 (PRG4) enzyme- linked immunosorbent assay control by protein staining (A) and characterization of high molecular weight PRG4 immunoreactivity in PRG4 control, normal (NL) human synovial fluid (hSF), and osteo- arthritic (OA) SF samples by Western blotting using antipeptide antibody LPN (capture) (B) and horseradish peroxidase (HRP)– conjugated peanut agglutinin (PNA) (detection) (C). Samples were subjected to 3–8% sodium dodecyl sulfate–polyacrylamide gel electro- phoresis, followed by protein staining or Western blotting as described in Materials and Methods. PRG4 controls treated with neuraminidase and SF treated with hyaluronidase and neuraminidase were probed with LPN and with HRP–conjugated PNA.
Human S100a9 Duoset Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/duoset+enzyme+linked+immunosorbent+assay+kits/Human+S100A9+DuoSet+ELISA/ppr0494104-51-15-19
Average 94 stars, based on 1 article reviews
human s100a9 duoset elisa - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

93
R&D Systems human phospho vegf r2 kdr duoset ic elisa kit
Figure 1. Characterization of the proteoglycan 4 (PRG4) enzyme- linked immunosorbent assay control by protein staining (A) and characterization of high molecular weight PRG4 immunoreactivity in PRG4 control, normal (NL) human synovial fluid (hSF), and osteo- arthritic (OA) SF samples by Western blotting using antipeptide antibody LPN (capture) (B) and horseradish peroxidase (HRP)– conjugated peanut agglutinin (PNA) (detection) (C). Samples were subjected to 3–8% sodium dodecyl sulfate–polyacrylamide gel electro- phoresis, followed by protein staining or Western blotting as described in Materials and Methods. PRG4 controls treated with neuraminidase and SF treated with hyaluronidase and neuraminidase were probed with LPN and with HRP–conjugated PNA.
Human Phospho Vegf R2 Kdr Duoset Ic Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/duoset+enzyme+linked+immunosorbent+assay+kits/Human+Phospho-VEGFR2%2FKDR+DuoSet+IC+ELISA/pm31822980-97-18-35
Average 93 stars, based on 1 article reviews
human phospho vegf r2 kdr duoset ic elisa kit - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

95
R&D Systems duoset elisa ancillary reagent kit
Higher anti-RBD IgM seroconversion rate in respiratory samples compared to paired blood samples of COVID-19 patients. a <t>ELISA</t> titration curves against the SARS-CoV-2 receptor-binding domain (RBD) for IgM, IgG, and IgA in COVID-19 respiratory and paired blood samples and non-COVID-19 respiratory samples. Dotted lines within each graph indicates the cut-off used to determine end-point titres. b Endpoint titres of SARS-CoV-2 RBD antibodies between (i) respiratory samples of COVID-19 and non-COVID-19 patients, and (ii) plasma and respiratory samples of COVID-19 patients. (i) Bars indicate median with interquartile range. Dotted line indicates the detection level. (ii) Dotted lines connect the most closely matched plasma and respiratory samples from each patient. Statistical significance was determined with Mann-Whitney test. c ELISA titration curves against the SARS-CoV-2 RBD for 3 COVID-19 patients with serial respiratory samples. d Heatmap of percentage (%) inhibition tested by surrogate virus neutralization test (sVNT) and anti-RBD ELISA titres. e Correlation between anti-RBD antibody titres and (%) sVNT inhibition. Correlation was determined with Spearman’s correlation. f Number of (i) samples and (ii) patients with seroconverted anti-RBD IgM, IgG, IgA and positive % sVNT inhibition. Pink curved lines surrounding the donut graphs indicate the samples/patients with seroconverted IgM. Earliest samples were used for each patient when determining seroconversion which was defined as average titre +2xSD of non-COVID-19 samples. Positive % sVNT inhibition was defined as % sVNT inhibition ≥ 20%.
Duoset Elisa Ancillary Reagent Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/duoset+enzyme+linked+immunosorbent+assay+kits/DuoSet+ELISA+Ancillary+Reagent+Kit+1/pmc08404907-236-0-5
Average 95 stars, based on 1 article reviews
duoset elisa ancillary reagent kit - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

94
R&D Systems duoset elisa canine il 2
Enhancement of cytokine production and cell proliferation of dog peripheral blood mononuclear cells by c4G12 treatment. Dog peripheral blood mononuclear cells ( n = 7) were obtained from healthy beagle donors and stimulated by 5 μg/mL staphylococcal enterotoxin B in the presence or absence of 20 μg/mL c4G12. Dog IgG was used as a control antibody. For evaluation of cytokine production, the culture supernatant was harvested on day 3, and concentration of ( a ) IL-2 or ( b ) IFN-γ was measured by <t>ELISA.</t> To evaluate cell proliferation, nucleotide analogue 5-ethynyl-2′-deoxyuridine (EdU) was added to the medium on day 2, and cells were harvested after incubation for another 2 h. The lymphocyte population was gated by forward scatter and side scatter, and the incorporation of EdU in ( c ) CD4+ or ( d ) CD8+ cells was measured by a flow cytometer. Statistical analysis was performed with a Wilcoxon signed rank-sum test.
Duoset Elisa Canine Il 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/duoset+enzyme+linked+immunosorbent+assay+kits/Canine+IL-2+DuoSet+ELISA/pmc05567082-215-21-27
Average 94 stars, based on 1 article reviews
duoset elisa canine il 2 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

Image Search Results


High concentration of CFTR modulators (Elexacaftor [VX445], Tezacaftor [VX661], and Ivacaftor [VX770]) impairs macrophage control of A. fumigatus growth. ( A ) Measurement of A. fumigatus fungal length (Strain: DAL-DSred) infecting bone marrow-derived macrophages (BMDM) at a multiplicity of infection (MOI) of 5, using the IncuCyte live-cell analysis system in the presence of 3VX (VX445/VX661/VX770) treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. * P < 0.05, ** P < 0.01 (two-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3. ( B ) Release of TNF⍺ in BMDMs was assessed after 20 h with A. fumigatus (MOI of 15). ** P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 4. ( C ) Normalized phagocytosis to vehicle control ([Veh]) at 20 h time point. **P < 0.01 , ****P < 0.005 (one sample t test, theoretical mean of 1); data are presented as mean ± SEM, n = 4. ( D ) Representative measurement of zymosan phagocytosis by primed BMDMs in the presence of 3VX treatment at concentrations [3VX] S , [3VX] E or [3VX] 10μM , as well as in the presence of cytochalasine D or [Veh]. ( E ) Quantification of viable conidia following 4 h of BMDM infection in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. ( F ) Immunoblot analysis of pro-caspase-1 ( P45 ), the caspase-1 subunit p20 ( P20 ), and β-actin of primed BMDMs left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh] during 20 h after infection with A. fumigatus (MOI of 15). ( G ) Release of IL-1β in BMDMs assessed after 20 h infection with A. fumigatus (MOI of 15) left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. *P < 0.05 , **P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3.

Journal: Microbiology Spectrum

Article Title: Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Aspergillus fumigatus growth

doi: 10.1128/spectrum.02275-24

Figure Lengend Snippet: High concentration of CFTR modulators (Elexacaftor [VX445], Tezacaftor [VX661], and Ivacaftor [VX770]) impairs macrophage control of A. fumigatus growth. ( A ) Measurement of A. fumigatus fungal length (Strain: DAL-DSred) infecting bone marrow-derived macrophages (BMDM) at a multiplicity of infection (MOI) of 5, using the IncuCyte live-cell analysis system in the presence of 3VX (VX445/VX661/VX770) treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. * P < 0.05, ** P < 0.01 (two-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3. ( B ) Release of TNF⍺ in BMDMs was assessed after 20 h with A. fumigatus (MOI of 15). ** P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 4. ( C ) Normalized phagocytosis to vehicle control ([Veh]) at 20 h time point. **P < 0.01 , ****P < 0.005 (one sample t test, theoretical mean of 1); data are presented as mean ± SEM, n = 4. ( D ) Representative measurement of zymosan phagocytosis by primed BMDMs in the presence of 3VX treatment at concentrations [3VX] S , [3VX] E or [3VX] 10μM , as well as in the presence of cytochalasine D or [Veh]. ( E ) Quantification of viable conidia following 4 h of BMDM infection in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. ( F ) Immunoblot analysis of pro-caspase-1 ( P45 ), the caspase-1 subunit p20 ( P20 ), and β-actin of primed BMDMs left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh] during 20 h after infection with A. fumigatus (MOI of 15). ( G ) Release of IL-1β in BMDMs assessed after 20 h infection with A. fumigatus (MOI of 15) left untreated (medium alone [Med]) or in the presence of 3VX treatment at [3VX] S , [3VX] E , or [3VX] 10μM , as well as with [Veh]. *P < 0.05 , **P < 0.01 (one-way ANOVA with Dunnett’s multiple comparisons test); data are presented as mean ± SEM, n = 3.

Article Snippet: Cytokine levels were determined by ELISA using kits according to the manufacturer’s instructions: TNF⍺ DuoSet ELISA (DY410, R&D Systems) and IL-1β (DY401, R&D Systems).

Techniques: Concentration Assay, Control, Derivative Assay, Infection, Cell Analysis, Western Blot

Figure 1. Characterization of the proteoglycan 4 (PRG4) enzyme- linked immunosorbent assay control by protein staining (A) and characterization of high molecular weight PRG4 immunoreactivity in PRG4 control, normal (NL) human synovial fluid (hSF), and osteo- arthritic (OA) SF samples by Western blotting using antipeptide antibody LPN (capture) (B) and horseradish peroxidase (HRP)– conjugated peanut agglutinin (PNA) (detection) (C). Samples were subjected to 3–8% sodium dodecyl sulfate–polyacrylamide gel electro- phoresis, followed by protein staining or Western blotting as described in Materials and Methods. PRG4 controls treated with neuraminidase and SF treated with hyaluronidase and neuraminidase were probed with LPN and with HRP–conjugated PNA.

Journal: Arthritis and rheumatism

Article Title: Diminished cartilage-lubricating ability of human osteoarthritic synovial fluid deficient in proteoglycan 4: Restoration through proteoglycan 4 supplementation.

doi: 10.1002/art.34674

Figure Lengend Snippet: Figure 1. Characterization of the proteoglycan 4 (PRG4) enzyme- linked immunosorbent assay control by protein staining (A) and characterization of high molecular weight PRG4 immunoreactivity in PRG4 control, normal (NL) human synovial fluid (hSF), and osteo- arthritic (OA) SF samples by Western blotting using antipeptide antibody LPN (capture) (B) and horseradish peroxidase (HRP)– conjugated peanut agglutinin (PNA) (detection) (C). Samples were subjected to 3–8% sodium dodecyl sulfate–polyacrylamide gel electro- phoresis, followed by protein staining or Western blotting as described in Materials and Methods. PRG4 controls treated with neuraminidase and SF treated with hyaluronidase and neuraminidase were probed with LPN and with HRP–conjugated PNA.

Article Snippet: A hyaluronan DuoSet ELISA development kit was obtained from R&D Systems, proteinase K was from Roche Applied Science, and MegaLadder and HiLadder HA molecular weight markers were from Hyalose.

Techniques: Enzyme-linked Immunosorbent Assay, Control, Staining, High Molecular Weight, Western Blot

Figure 3. Characterization of hyaluronan (HA) in normal and PRG4- deficient OA SF samples. A, Concentrations of HA in normal and PRG4-deficient OA SF samples. B, Molecular weight distribution of HA in normal SF samples (n 8) and in PRG4-deficient OA (OA-LO) SF samples (n 5). Values are the mean SEM. P 0.05. See Figure 1 for other definitions.

Journal: Arthritis and rheumatism

Article Title: Diminished cartilage-lubricating ability of human osteoarthritic synovial fluid deficient in proteoglycan 4: Restoration through proteoglycan 4 supplementation.

doi: 10.1002/art.34674

Figure Lengend Snippet: Figure 3. Characterization of hyaluronan (HA) in normal and PRG4- deficient OA SF samples. A, Concentrations of HA in normal and PRG4-deficient OA SF samples. B, Molecular weight distribution of HA in normal SF samples (n 8) and in PRG4-deficient OA (OA-LO) SF samples (n 5). Values are the mean SEM. P 0.05. See Figure 1 for other definitions.

Article Snippet: A hyaluronan DuoSet ELISA development kit was obtained from R&D Systems, proteinase K was from Roche Applied Science, and MegaLadder and HiLadder HA molecular weight markers were from Hyalose.

Techniques: Molecular Weight

Figure 4. Effect of hyaluronan (HA) and proteoglycan 4 (PRG4) supplementation on the cartilage boundary–lubricating ability of PRG4-deficient osteoarthritic (OA) synovial fluid (SF) samples, as determined by cartilage-on-cartilage friction testing. Two friction coefficients (), static (static, Neq) (A) and kinetic (kinetic, Neq ; at a presliding duration of 1.2 seconds) (B), in phosphate buffered saline (PBS; negative control lubricant), PRG4-deficient OA (OA-LO) SF alone, PRG4-deficient OA SF plus PRG4, PRG4-deficient OA SF plus PRG4 and HA, and normal SF (NL; positive control lubricant) were calculated. Values are the mean SEM. P 0.05. Neq represents equilibrium axial load; angle brackets indicate that the value is an average.

Journal: Arthritis and rheumatism

Article Title: Diminished cartilage-lubricating ability of human osteoarthritic synovial fluid deficient in proteoglycan 4: Restoration through proteoglycan 4 supplementation.

doi: 10.1002/art.34674

Figure Lengend Snippet: Figure 4. Effect of hyaluronan (HA) and proteoglycan 4 (PRG4) supplementation on the cartilage boundary–lubricating ability of PRG4-deficient osteoarthritic (OA) synovial fluid (SF) samples, as determined by cartilage-on-cartilage friction testing. Two friction coefficients (), static (static, Neq) (A) and kinetic (kinetic, Neq ; at a presliding duration of 1.2 seconds) (B), in phosphate buffered saline (PBS; negative control lubricant), PRG4-deficient OA (OA-LO) SF alone, PRG4-deficient OA SF plus PRG4, PRG4-deficient OA SF plus PRG4 and HA, and normal SF (NL; positive control lubricant) were calculated. Values are the mean SEM. P 0.05. Neq represents equilibrium axial load; angle brackets indicate that the value is an average.

Article Snippet: A hyaluronan DuoSet ELISA development kit was obtained from R&D Systems, proteinase K was from Roche Applied Science, and MegaLadder and HiLadder HA molecular weight markers were from Hyalose.

Techniques: Saline, Negative Control, Positive Control

Higher anti-RBD IgM seroconversion rate in respiratory samples compared to paired blood samples of COVID-19 patients. a ELISA titration curves against the SARS-CoV-2 receptor-binding domain (RBD) for IgM, IgG, and IgA in COVID-19 respiratory and paired blood samples and non-COVID-19 respiratory samples. Dotted lines within each graph indicates the cut-off used to determine end-point titres. b Endpoint titres of SARS-CoV-2 RBD antibodies between (i) respiratory samples of COVID-19 and non-COVID-19 patients, and (ii) plasma and respiratory samples of COVID-19 patients. (i) Bars indicate median with interquartile range. Dotted line indicates the detection level. (ii) Dotted lines connect the most closely matched plasma and respiratory samples from each patient. Statistical significance was determined with Mann-Whitney test. c ELISA titration curves against the SARS-CoV-2 RBD for 3 COVID-19 patients with serial respiratory samples. d Heatmap of percentage (%) inhibition tested by surrogate virus neutralization test (sVNT) and anti-RBD ELISA titres. e Correlation between anti-RBD antibody titres and (%) sVNT inhibition. Correlation was determined with Spearman’s correlation. f Number of (i) samples and (ii) patients with seroconverted anti-RBD IgM, IgG, IgA and positive % sVNT inhibition. Pink curved lines surrounding the donut graphs indicate the samples/patients with seroconverted IgM. Earliest samples were used for each patient when determining seroconversion which was defined as average titre +2xSD of non-COVID-19 samples. Positive % sVNT inhibition was defined as % sVNT inhibition ≥ 20%.

Journal: Research Square

Article Title: Immune responses in COVID-19 respiratory tract and blood reveal mechanisms of disease severity

doi: 10.21203/rs.3.rs-802084/v1

Figure Lengend Snippet: Higher anti-RBD IgM seroconversion rate in respiratory samples compared to paired blood samples of COVID-19 patients. a ELISA titration curves against the SARS-CoV-2 receptor-binding domain (RBD) for IgM, IgG, and IgA in COVID-19 respiratory and paired blood samples and non-COVID-19 respiratory samples. Dotted lines within each graph indicates the cut-off used to determine end-point titres. b Endpoint titres of SARS-CoV-2 RBD antibodies between (i) respiratory samples of COVID-19 and non-COVID-19 patients, and (ii) plasma and respiratory samples of COVID-19 patients. (i) Bars indicate median with interquartile range. Dotted line indicates the detection level. (ii) Dotted lines connect the most closely matched plasma and respiratory samples from each patient. Statistical significance was determined with Mann-Whitney test. c ELISA titration curves against the SARS-CoV-2 RBD for 3 COVID-19 patients with serial respiratory samples. d Heatmap of percentage (%) inhibition tested by surrogate virus neutralization test (sVNT) and anti-RBD ELISA titres. e Correlation between anti-RBD antibody titres and (%) sVNT inhibition. Correlation was determined with Spearman’s correlation. f Number of (i) samples and (ii) patients with seroconverted anti-RBD IgM, IgG, IgA and positive % sVNT inhibition. Pink curved lines surrounding the donut graphs indicate the samples/patients with seroconverted IgM. Earliest samples were used for each patient when determining seroconversion which was defined as average titre +2xSD of non-COVID-19 samples. Positive % sVNT inhibition was defined as % sVNT inhibition ≥ 20%.

Article Snippet: DuoSet ELISA ancillary reagent kit (R&D Systems) was used for respiratory fluids and in-house reagents with the same composition were used for plasma samples.

Techniques: Enzyme-linked Immunosorbent Assay, Titration, Binding Assay, Clinical Proteomics, MANN-WHITNEY, Inhibition, Virus, Neutralization

Enhancement of cytokine production and cell proliferation of dog peripheral blood mononuclear cells by c4G12 treatment. Dog peripheral blood mononuclear cells ( n = 7) were obtained from healthy beagle donors and stimulated by 5 μg/mL staphylococcal enterotoxin B in the presence or absence of 20 μg/mL c4G12. Dog IgG was used as a control antibody. For evaluation of cytokine production, the culture supernatant was harvested on day 3, and concentration of ( a ) IL-2 or ( b ) IFN-γ was measured by ELISA. To evaluate cell proliferation, nucleotide analogue 5-ethynyl-2′-deoxyuridine (EdU) was added to the medium on day 2, and cells were harvested after incubation for another 2 h. The lymphocyte population was gated by forward scatter and side scatter, and the incorporation of EdU in ( c ) CD4+ or ( d ) CD8+ cells was measured by a flow cytometer. Statistical analysis was performed with a Wilcoxon signed rank-sum test.

Journal: Scientific Reports

Article Title: A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma

doi: 10.1038/s41598-017-09444-2

Figure Lengend Snippet: Enhancement of cytokine production and cell proliferation of dog peripheral blood mononuclear cells by c4G12 treatment. Dog peripheral blood mononuclear cells ( n = 7) were obtained from healthy beagle donors and stimulated by 5 μg/mL staphylococcal enterotoxin B in the presence or absence of 20 μg/mL c4G12. Dog IgG was used as a control antibody. For evaluation of cytokine production, the culture supernatant was harvested on day 3, and concentration of ( a ) IL-2 or ( b ) IFN-γ was measured by ELISA. To evaluate cell proliferation, nucleotide analogue 5-ethynyl-2′-deoxyuridine (EdU) was added to the medium on day 2, and cells were harvested after incubation for another 2 h. The lymphocyte population was gated by forward scatter and side scatter, and the incorporation of EdU in ( c ) CD4+ or ( d ) CD8+ cells was measured by a flow cytometer. Statistical analysis was performed with a Wilcoxon signed rank-sum test.

Article Snippet: For cytokine assays, the culture supernatant was harvested on day 3 and the concentrations of IL-2 and IFN-γ were measured by Duoset ELISA canine IL-2 and IFN-γ (R&D systems, Minneapolis, MN, USA), respectively, according to the manufacturer’s instructions.

Techniques: Control, Concentration Assay, Enzyme-linked Immunosorbent Assay, Incubation, Flow Cytometry